<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099641</url>
  </required_header>
  <id_info>
    <org_study_id>ONCG100</org_study_id>
    <secondary_id>2019-000949-13</secondary_id>
    <secondary_id>KEYNOTE PN978</secondary_id>
    <nct_id>NCT04099641</nct_id>
  </id_info>
  <brief_title>An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients</brief_title>
  <official_title>A Phase 2, Multicenter Open-label, Non-randomized Study of Bavituximab Plus Pembrolizumab in Patients With Advanced Gastric or Gastroesophageal Cancer Who Have Progressed on or After at Least One Prior Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncologie Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oncologie Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the combination of bavituximab and pembrolizumab in the treatment of
      gastric and gastroesphogeal cancer. All patients will receive both bavituximab, a drug that
      is not yet approved by the FDA, and pembrolizumab known as Keytruda.

      There is no expanded access program available for the investigational agents per this
      protocol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of Treatment Emergent Adverse Events(TEAE)</measure>
    <time_frame>From first dose through 30 days after last dose</time_frame>
    <description>Incidence by severity of TEAEs graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, including changes in clinical laboratory parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months</time_frame>
    <description>Objective response rate (ORR) as assessed by the Investigator per RECIST version1.1</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>GastroEsophageal Cancer</condition>
  <arm_group>
    <arm_group_label>bavituximab and pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bavituximab 3mg/kg IV weekly in combination with pembrolizumab 200mg IV given once every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bavituximab</intervention_name>
    <description>Bavituximab IV infusion</description>
    <arm_group_label>bavituximab and pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab Injection</intervention_name>
    <description>Pembrolizumab IV Infusion</description>
    <arm_group_label>bavituximab and pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  Men and women ≥ 18 years old; ≥ 20 years old in South Korea and Taiwan

          -  Unresectable metastatic or locally advanced gastric or GEJ adenocarcinoma

          -  Progressed on and/or after at least 1 prior regimen for metastatic disease

          -  Willing and able to provide fresh formalin-fixed paraffin-embedded tissue tumor sample

          -  Presence of at least one measurable lesion

          -  ECOG of 0 or 1

          -  Has adequate organ functions

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             within 72 hours prior to start of study treatment.

          -  Women must not be breastfeeding.

          -  Women of childbearing potential , must agree to follow instructions for highly
             effective method(s) of contraception

          -  Males who are sexually active with women of childbearing potential must agree to
             follow instructions for highly effective method(s) of contraception

          -  Has adequate treatment washout period before start of study treatment

        Exclusion Criteria:

          -  Received any form of anti-phosphatidylserine therapies

          -  Prior treatment with any checkpoint inhibitor or other therapies targeting T-cell
             control

          -  Known microsatellite instability-high (MSI-H) gastric or GEJ adenocarcinoma

          -  Medical history of myocardial infarction within 6 months before registration,
             symptomatic congestive heart failure (CHF) , troponin levels consistent with
             myocardial infarction, unstable angina, or serious cardiac arrhythmia

          -  Weight loss &gt;10% over 2 months prior to first dose of study treatment

          -  History of pneumonitis that required steroids or has current pneumonitis

          -  Has known active CNS metastases/and or carcinomatous meningitis

          -  Known additional malignancy that is progressing or has required active treatment in
             within the past 3 years

          -  An active infection requiring systemic therapy

          -  Known human immunodeficiency virus (HIV) infection or known acute hepatitis B or C
             infection

          -  Unresolved toxicities from previous cancer treatments

          -  History or current evidence of any condition, therapy, or laboratory abnormality that
             might confound the results of the study, interfere with the participant's
             participation for the full duration of the study, or is not in the best interest of
             the participant to participate, in the opinion of the treating investigator

          -  Active autoimmune disease or history of chronic recurrent autoimmune disease

          -  Severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients.

          -  History of infusion reactions to any component/excipient of bavituximab

          -  History of severe hypersensitivity reactions to mAbs.

          -  Systemic steroid therapy within 7 days prior to the first dose of study treatment

          -  Has received a live vaccine within 30 days prior to first dose of study drug.

          -  Prior organ transplantation including allogeneic or autologous stem-cell
             transplantation

          -  Currently participating in or has participated in a study of an investigational agent
             or has used an investigational device within 4 weeks prior to the first dose of study
             treatment

          -  Receipt of treatment with immunotherapy, biological therapies, or therapeutic doses of
             hormonal therapies within 3 weeks of scheduled C1D1 dosing

          -  Known psychiatric, substance abuse disorder, or geographical travel limitations that
             would interfere with participant's ability to cooperate with the requirements of the
             study

          -  Pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oncologie Inc.</last_name>
    <phone>1-781-907-7810</phone>
    <email>medical@oncologie.international</email>
  </overall_contact>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale-New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida - Weston</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - Washington University Medical Campus</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>White Plains Hospital - Center for Cancer Care</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America at Eastern Regional Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sara Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Bavituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

